Nephrology Society Released New CKM Health Guidance
The American Society of Nephrology introduced updated clinical guidelines for managing cardiovascular-kidney-metabolic health.
Updated on Sept. 21, 2026 in Heart Disease
Live Poll
Do you trust that current medical guidelines adequately coordinate care across different chronic health conditions?
The American Society of Nephrology has issued new medical guidance for treating cardiovascular-kidney-metabolic (CKM) syndrome. The recommendations aim to provide nephrologists with specific protocols for integrated risk assessment and treatment.
Why it matters
Chronic kidney disease is now recognized as a major CKM risk factor that requires comprehensive cardiovascular assessment. This guidance specifically addresses treatment pathways for patients who are often underrepresented in large clinical trials.
The clinical guidance targets lipid-lowering therapies specifically for patients with nondialysis dependent-CKD stages 3 to 5 who also have atherosclerotic CVD. Long-term efficacy metrics for these specific populations remain an area of ongoing study.
The players
American Society of Nephrology
This is a professional organization representing kidney specialists that promotes the study and practice of nephrology.
The details
Nephrologists are advised to utilize a range of assessment tools, including eGFR, urine albumin-creatinine ratio, blood pressure, BMI, HbA1c, and lipid profiles. The guidance integrates the use of the CVD PREVENT equation and Kidney Failure Risk Equations alongside foundational treatments like SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists.
Timeline
September 21, 2026: The American Society of Nephrology released the new medical guidance.
The Big Picture
The Journal of the American Society of Nephrology serves as the platform for publishing the latest clinical standards for CKM syndrome, establishing a formal benchmark for nephrological practice. This release follows the established pattern of the journal setting definitive clinical standards for the nephrology community.
Patients may notice their nephrologists incorporating more frequent cardiovascular screenings like lipid profiles and blood pressure monitoring during routine visits. Those prescribed new foundational treatments like SGLT2 inhibitors should be aware that initial eGFR dips are expected.
The takeaway
Patients should discuss these new integrated treatment options with their nephrologist to understand how CKM syndrome affects their overall health. Consistency with lifestyle modifications and prescribed medication sequences is critical for slowing disease progression.
Further reading
For more information on managing systemic risk factors, visit the Heart Disease section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that current medical guidelines adequately coordinate care across different chronic health conditions?
